

Laguna Hills

Clinical Research Treatment Trial Flowchart

MYELOPROLIFERATIVE NEOPLASM: FRONT LINE

ETCTN 10538

Venetoclax+ASTX727 (All oral therapy) for CMML, PDS/MPN with excess blasts

Mechanism: BCL-2 selective inhibitor

PI: Jeyakumar
Coord: S. Osorio
Accrual: 0/5

NEWLY DIAGNOSED: HIGH RISK

ETCTN 10612

Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) vs Daratumumab, Lenalidomide, Velcade, and Dexamethasone (Dara-RVD)

Mechanism: selective inhibitor of nuclear export (SINE) compound + IgG1κ monoclonal antibody (mAb) + proteasome inhibitor

PI: Lee
Coord: Y. Ting
Accrual: 1/5

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

CLL NEWLY DIAGNOSED: HIGH RISK

SWOG S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Mechanism: BCL2 inhibitor +anti-CD20 monoclonal antibody

PI: Coombs
Coord: K. McAbee
Accrual: 2/10

CRC: ADJUVANT

NRG G1008/CIRCULATE

(ctDNA guided tx)

PI: Zell

Coord: A. Luna

Accrual: 2/5

MELANOMA: NON-TREATMENT

UCI 19-135

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

PI: Yamamoto
Coord: A. Reipolska
Accrual: 84/90